CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Leukocytes decline > 2500/µl during Peginterferon Alfa-2B (PEG-2B)/Ribavirin (RBV) treatment predicts favorable SVR rates in difficult-to-treat patients with HCV Genotype 1 (G1) infection in real-life
DOI 10.1055/s-0033-1352952
Bibliografische Angaben
Nachweis in CareLit
Autor:innenG Teuber, S Mauss, D Hüppe, E Zehnter, MP Manns, T Dahhan, U Meyer, T Witthöft, B Möller, N Dikopoulos, J Brack, D Hartmann, B Dreher, M Bilzer
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background and aims: Leukocyte decline during antiviral treatment of chronic HCV infection may reflect pharmacodynamic effects of pegylated interferons. We therefore investigated the possible association between leukocyte decline and SVR in difficult-to-treat patients (pts) undergoing Peg2b/RBV therapy for HCV G1 infection in real-life. Methods: Data from the German Peg2b/RBV observational study were retrospectively…
Zitieren
Zitierempfehlung
G Teuber, S Mauss, D Hüppe, E Zehnter, MP Manns, T Dahhan, U Meyer, T Witthöft, B Möller, N Dikopoulos, J Brack, D Hartmann, B Dreher, M Bilzer (2013) Leukocytes decline > 2500/µl during Peginterferon Alfa-2B (PEG-2B)/Ribavirin (RBV) treatment predicts favorable SVR rates in difficult-to-treat patients with HCV Genotype 1 (G1) infection in real-life. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0033-1352952
Mit CareLit weiterarbeiten